Glycominds, a molecular diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market. Our proprietary tests allow physicians to help identify patients at a higher risk for more severe disease outcomes.

Glycominds’ current products include tests to help develop personalized therapy approaches for patients with Multiple Sclerosis and Crohn's Disease. These tests are easy to administer and non-invasive. Glycominds’ tests help physicians identify patients who have Multiple Sclerosis and which of these patients are likely to progress towards disability. These patients require more aggressive treatment and several new aggressive treatment options are becoming available to physicians. Glycominds’ tests help physicians identify patients who have Crohn’s Disease and which of the patients are at higher risk for bowel damages and surgery. These patients can be candidates for "top down" therapy with biologics.

Glycominds passion is slowing and ultimately preventing the progression of Multiple Sclerosis and Crohn's Disease and developing similar tools in the future other chronic autoimmune and inflammatory diseases.